TrialID,"Last Refreshed on","Public title","Scientific title",Acronym,"Primary sponsor","Date registration","Date registration3","Export date","Source Register","web address","Recruitment Status","other records","Inclusion agemin","Inclusion agemax","Inclusion gender","Date enrollement","Target size","Study type","Study design",Phase,Countries,"Contact Firstname","Contact Lastname","Contact Address","Contact Email","Contact Tel","Contact Affiliation","Inclusion Criteria","Exclusion Criteria",Condition,Intervention,"Primary outcome","Secondary outcome","Secondary ID","Source Name","Secondary Sponsor","Ethics Status","Ethics Approval Date","Ethics Contact Name","Ethics Contact Address","Ethics Contact Phone","Ethics Contact Email","results yes no","results date posted","results url link","results url protocol","results date completed","results date first publication","results summary","results baseline char","results adverse events","results outcome measures","results ipd plan","results ipd description","Prospective registration","Bridging flag truefalse","Bridged type"
PACTR201811769142678,"24 June 2025","Effectiveness of a locally developed health education package in the control of Taenia solium infections in humans and pigs in Tanzania","Development and evaluation of a locally adapted health education package for control of Taenia solium taeniasis and cysticercosis in Tanzania                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",,"Helena A. Ngowi",30/11/2018,"  20181130","10/13/2025 16:03:22",PACTR,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3559,"Not Recruiting",No,"6 Year(s)","12 Year(s)",Both,01/01/2019,1462,Interventional,"Parallel: different groups receive different interventions at same time during study,Non-randomised,Allocation was determined by the holder of the sequence who is situated off site",Phase-3,"United Republic of Tanzania;United Republic of Tanzania",Ernatus,Mkupasi,"Sokoine University of Agriculture, P. O. Box 3021",emkupasi@yahoo.com,+255763929,Lecturer,"Inclusion criteria: Residing in the study districts (Kongwa and Songwe), Tanzania<br>Aged 6-65 years<br>Willing to participate","Exclusion criteria: Residing outside the study districts (Kongwa and Songwe), Tanzania<br>Aged below 6 or above 65 years<br>Unwilling to participate"," <br>Digestive System <br>Musculoskeletal Diseases <br>Nervous System Diseases <br>Skin and Connective Tissue Diseases;Digestive System;Musculoskeletal Diseases;Nervous System Diseases;Skin and Connective Tissue Diseases",";Health education;Monitoring alone","Cumulative incidence of Taenia solium cysticercosis seroconversion in humans compared between the intervention and control groups.","Change in knowledge, attitudes and practices related to Taenia solium.;Change in the prevalence of cysticercosis in pigs",NIMRHQR.8aVol.IX2802,"German Federal Ministry of Education and Research BMBF",,Approved;Approved,22/06/2018;17/07/2017,"National Institute for Medical Research;Research Innovation and Publication Committee","3 Barack Obama Drive;Sokoine University of Agriculture",+255222121400;+255232603511,ethics@nimr.or.tz;deanfvm@sua.ac.tz,,,,,,,,,,,No,,Yes,False,"          "
PACTR201712002788898,"24 June 2025","Evaluation of an antibody detecting point-of-care test for the diagnosis of Taenia solium taeniosis and (euro)cysticercosis in Tanzania and Zambia","Evaluation of an antibody detecting point-of-care test for the diagnosis of Taenia solium taeniasis and (neuro)cysticercosis in communities and district hospitals of highly endemic, resource-poor areas in sub Saharan Africa, including capacity building                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ",,"Institute of Tropical Medicine",21/11/2017,"  20171121","10/13/2025 16:03:22",PACTR,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=2788,"Not Recruiting",No,"10 Year(s)","140 Year(s)",Both,02/12/2017,3800,Interventional,"Parallel: different groups receive different interventions at same time during study,Randomised,Diagnostic study with randomised and non-randomised part, randomisation based on household codes, tallying and coin-tossing,NA, diagnostic study","Not Applicable",Zambia;Tanzania;Tanzania;Tanzania,Sarah,GABRIEL," Salisburylaan 133",sarah.gabriel@ugent.be,+3292647737,"Ghent University","Inclusion criteria: Tanzania NCC:<br>Patients 10 years of age and above with on-going symptoms of severe progressive headache impeding the daily activities without fever and without signs of cerebral infection or other obvious causes OR patients 10 years of age and above with a history of one or more epileptic seizures without obvious causes<br>¿ Patients willing and able to participate in all aspects of the study, including providing blood and stool samples, participating in a questionnaire survey, and undergoing brain<br>CT Scan if indicated<br>¿ Patients willing and able to provide written informed consent<br>¿ Patients living in the study area for the past three months and planning to stay in the same area throughout the study period<br>Tanzania T:<br>Patient must be 10 years and above and present at the out-patient clinic with<br>(1) intestinal complaints compatible with intestinal worm infection (diarrhoea > 2 weeks and/or abdominal pain/discomfort > 2 weeks and/or recent history of worm expulsion): SELECTIVE GROUP<br>(2) any other symptom not immediately linked with intestinal worm infection: RANDOM GROUP <br>¿ Patients willing and able to provide written informed consent<br>¿ Patients living in the study area for the past three months and planning to stay in the same area throughout the study period<br>Zambia (N)CC and T: <br>Patients willing and able to participate in all aspects of the study, including providing blood and stool samples, participating in a questionnaire survey, and undergoing brain CT scan if indicated <br>¿ Willing and able to provide written informed consent <br>Living, attending school, or regularly visiting the bore holes present in the study<br>communities<br>¿ Aged 10 years of age or older<br>PhD study:<br>Individuals involved in the preparation of pork and that usually also eat pork<br>¿ Individuals older than 18 years of age<br>¿ Individuals willing and able to provide written informed consent<br> ","Exclusion criteria: Tanzania NCC: <br>¿ Patients less than 10 years of age<br>¿ Patients with any acute febrile illness<br>¿ Patients with fever and signs and symptoms for middle ear infection<br>¿ Patients with signs and symptoms of meningitis<br>¿ Patients with neck muscle pain and stiffness<br>¿ Patients with a history of stroke with neurological focal deficit<br>¿ Patients not willing or able to provide written informed consent (assent for minors)<br>¿ Patients not resident in the study area<br>¿ Patients reported pregnant<br>Tanzania T: <br>Patients below the age of 10 years<br>¿ Patients with acute severe illness that need in-patient care<br>¿ Patients not willing or able to provide written informed consent (assent for minors)<br>¿ Patient not resident in the study area<br>Zambia:<br>Unwilling or unable to participate in some or all aspects of the study, including<br>providing blood and stool samples, participating in a questionnaire survey, and<br>undergoing brain CT scan if indicated (clinically or per protocol)<br>¿ Unwilling or unable to provide written informed consent (assent for minors with<br>consent from a parent or a legally authorised representative)<br>¿ Living outside of, and not regularly visiting, or attending school in, the study<br>communities<br>¿ Children below the age of 10 years<br>¿ Children below the age of 10 years with severe malnutrition<br>¿ Reported pregnant<br>Seriously ill (unable to engage in the normal activities of daily living without<br>assistance because of the illnesses)<br>PhD:<br>Individuals below the age of 18 years<br>¿ Individuals not willing or able to provide written informed consent<br>¿ Individuals that previously participated in T. solium research projects"," <br>neurocysticercosis, taeniosis <br>neurocysticercosis, taeniosis;neurocysticercosis, taeniosis;neurocysticercosis, taeniosis",";Diagnostic study Tanzania;Diagnostic study Zambia","POC test sensitivity and specificity for the detection of taeniosis and (neuro) csyticercosis at community level (Zambia) and at district hospital level (Tanzania)","Tanzania: Behavioural change following health education",,"EDCTP;Bundesministerium fur Bildung und Forschung BMBF",,Approved;Approved;Approved,13/09/2017;18/09/2017;10/10/2017,"University of Zambia Biomedical Research Ethics Committee;Universiteit Antwerpen Ethisch Comite;National Health Research Ethics CommitteeNational Institute for Medical Research"," University of Zambia, Ridgeway Campus, POBox 50110 Lusaka, Zambia;UZA, Wilrijkstraat 10; 3 Barack Obama Drive",+260012560670;+323813000;+255222121400,unzarec@unza.zm;etisch.comite@uza.be;ethics@nimr.or.tz,,,,,,,,,,,,,Yes,False,"          "
PER-082-13,"4 September 2023","EMPIRICAL AND TARGETED TREATMENT FOR TAENIA SOLIUM SOLITARIA (PERU)","EMPIRICAL AND TARGETED TREATMENT FOR TAENIA SOLIUM SOLITARIA (PERU)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",,"UNIVERSIDAD PERUANA CAYETANO HEREDIA,",27/02/2014,"  20140227","10/13/2025 16:03:22",REPEC,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=082-13,,No,2,100,--,01/01/2014,2000,Interventional,"The study is a group or cluster  randomized clinical trial to evaluate a community-based strategy to control transmission of the parasite T.solium",IV,Peru,"Hector Hugo",Garcia,Alan,hgarcia@jhsph.edu,3287360,"UNIVERSIDAD PERUANA CAYETANO HEREDIA ","Inclusion criteria: All community residents older than 2 years of age or weighing more than 11 kg.","Exclusion criteria: Inability to provide informed consent.","-B680 Taenia solium taeniasis <br>Taenia solium taeniasis;B680;Taenia solium taeniasis","<br>Niclosamide 500 mg, presentation tablets, single dose according to weight:<br>11-34 kg (02 tablets or 1 gram)<br>35-49 kilos (03 tablets)<br>more than 50 kilos (04 tablets)<br>If we find a positive Pig opens a ring and all the people who live within this ring (100 m around the infected pig), niclosamide will be given: the first ring aperturar dose and the second dose at 15 days.<br>",,,,"UBS Optimus Foundation",,Approved,27/08/2013,"Universidad Peruana Cayetano Heredia"," Av. Honorio Delgado 430 Urb. I","3190000 anexo 2271","hguerra@upch.edu.pe ",,,,,,,,,,,,,No,False,"          "
NCT01296958,"19 February 2015","Targeted Screening for Taenia Solium Tapeworms","Targeted Screening for Taenia Solium Tapeworms",,"Oregon Health and Science University",15/02/2011,"  20110215","10/13/2025 16:03:22",ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01296958,"Not recruiting",No,N/A,N/A,Both,01/05/2011,1811,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening",N/A,Peru," ; ","Seth E ONeal, MD MPH;Armando Gonzalez, DVM PhD",,;,;,"Oregon Health and Science University;San Marcos University School of Veterinary Medicine","<br>    Inclusion Criteria:<br><br>     - All community members are eligible<br><br>    Exclusion Criteria:<br><br>     - Inability to provide informed consent<br>   ",,"Taenia Solium Taeniasis","Drug: Niclosamide;Behavioral: Community education campaign","Porcine seroprevalence","Intestinal tapeworm prevalence",1R21NS069275-01;1R21NS069275-01,"Please refer to primary and secondary sponsors","Universidad Nacional Mayor de San Marcos;National Institute of Neurological Disorders and Stroke (NINDS)",,,,,,,,,,,,,,,,,,,Yes,False,"          "
PER-002-05,"4 September 2023","ELIMINATION OF CYSTICERCOSIS IN PERU","ELIMINATION OF CYSTICERCOSIS IN PERU                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",,"BILL & MELINDA GATES FOUNDATION,",07/02/2005,"  20050207","10/13/2025 16:03:22",REPEC,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=002-05,"Not Recruiting",No,0,0,--,24/10/2012,160000,Interventional,"It is a multicenter, non-randomized, openstudy of parallel groups to evaluate the effectiveness of cysticercosis and taeniasis control strategies based on tools that include: identification, mass treatment and targeted treatment in human and porcine population",0,Peru,MONICA,VERA,Alan,mvera@,"993520629/ 3288589","UNIVERSIDAD PERUANA CAYETANO HEREDIA ","Inclusion criteria: <br>- Resident of the rural areas of Tumbes, Talara and Sullana (who stays at least two nights in the<br>community)<br>- Resident over two years.<br>","Exclusion criteria: <br>- Residents who refuse to participate in the study.<br>- Women in gestation will not receive massive treatment of niclosamide.<br>- Participants with a history of adverse effects to nidosamide will not participate in the mass treatment.<br>","-B68 Taeniasis-B690 Cysticercosis of central nervous system <br>Taeniasis <br>Cysticercosis of central nervous system;B68 ;B690;Taeniasis;Cysticercosis of central nervous system","<br>Group name:Year 1, minimum intervention model. Group of Humans Type of group;1 N° of participants:2400 Intervention(s) description:This group will be treated with massive treatments of Niclosamide 1 to 2 g PO according to weight (Children between 11 and 34 kg: 1 g, Children over 34 kg: 1.5 g, Adults: 2 g), every 4 months for a total of 2 doses The treatment of this group will begin 1 month after the treatment of the pigs of the same communities.<br>Group name:Year of Stagnation 2. Population of Talar and Sullana<br>Type of group;1 N° of participants:60000 Intervention(s) description:In human population: Three rounds of mass treatment of taeniasis with niclosamide 1 to 2 g PO QD according to weight will be applied (Children between 11 and 34 kg: 1 g, Children over 34 kg: 1.5 g, Adults: 2 g) , months 1, 5 and 9.<br><br>In swine population Five rounds of massive treatment with Oxfendazole at maximum dose PO, months 0, 2, 4, 6, and 8. Recombinant vaccine TS0L18 IM months 0 and 4. Vaccine against swine cholera months 0, 2 and 4 .<br>","<br>Outcome name:Application of 6 different models for the control of taeniasis in human and porcine population. After this the 2 most successful models of intervention are applied at large scale<br>Measure:Development and evaluation of a new control strategy for the treatment of taeniasis and human and porcine neurocysticercosis<br>Timepoints:48 months<br>","<br>Outcome name:Serological samples in blood, urine and faeces in humans and swine population: Western Blot technique to detect antibodies against teniosis. Concentration technique for the detection of eggs. Copro antigen technique.<br>Necropsy of swine population.<br><br>Measure:Demonstration of the interruption of the transmission of T. solium.<br>Timepoints:The samples of blood, feces, urine both porcine and human were taken according to the different calendars of each of the 6 models during the 4 years of intervention. Samples could be taken before or after the administration of treatment.<br>;<br>Outcome name:Determination of incidence and prevalence of epileptic seizure events in the study area and through periodic monitoring of the incidence and prevalence of porcine cysticercosis seropositivity in Western Blot tests to detect antibodies against teniosis, of concentration for the detection of eggs, co-antigen test and necropsy of porcine population.<br><br>Measure:Impact of the intervention<br>Timepoints:An evaluation will be made after the intervention during each year to estimate the prevalence and incidence of taeniasis and human or porcine cysticercosis.<br>The samples of blood, feces, urine both porcine and human were taken according to the different calendars of each of the 6 models during the 4 years of intervention. They can be taken before or after the administration of treatment.<br>;<br>Outcome name:Efficacy of the treatment: Seropositivity in the Western Blot, egg concentration, coproantigen and necropsy tests of the swine population.<br>Economic impact: Socio-economic census that will include characteristics of geographical location, characteristics of housing, family members, raising pigs and other animals, characteristics and location of breeding sites, breeding conditions, type of feeding and water status .<br>Measure:<br>776/5000<br>Efficacy of the treatment. Economic impact of the interventions.<br><br>Timepoints:The samples of blood, feces, urine both porcine and human were taken according to the different calendars of each of the 6 models during the 4 years of intervention.<br>The impact survey is carried out before each intervention.<br>;<br>Outcome name:Survey to determine the prevalence of epilepsy in all the villages intervened.<br>Neurological evaluation Electroencephalogram. Serum, faeces and urine samples for detection of T. solium infection.<br>Quality of life survey.<br>Measure:Prevalence of epilepsy. Etiology of seizures. Impact on the quality of life in patients with a diagnosis of epilepsy.<br>Timepoints:These interventions will be carried out during Year 1.<br>",,,,Approved;Approved,03/09/2006;16/04/2013,"Universidad Peruana Cayetano Heredia;Universidad Peruana Cayetano Heredia"," Av. Honorio Delgado 430 Urb. I; Av. Honorio Delgado 430 Urb. I","3190000 anexo 2271;3190000 anexo 2271","hguerra@upch.edu.pe ;hguerra@upch.edu.pe ",,,,NA,,,,,,,No,,Yes,False,"          "
